169749-99-9

Basic information

• Product Name: (3S)-(+)-1-Benzyl-3-(methylamino)pyrrolidine
• Synonyms: (3S)-(+)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE;(S)-1-BENZYL-3-METHYLAMINOPYRROLIDINE;(S)-1-benzyl-N-methylpyrrolidin-3-amine;(S)-N-Benzyl-3-methylaminopyrrolidine;(S)-(1-Benzyl-pyrrolidin-3-yl)-methyl-amine;(3S)-1-benzyl-N-Methylpyrrolidin-3-aMine;(3S)-1-Benzyl-N-methyl-3-pyrrolidinamine;(3S)-(+)-1-Benzyl-3-(methylamino)pyrrolidine
• CAS NO: 169749-99-9
• Molecular Formula: C₁₂H₁₈N₂
• Molecular Weight: 190.28
• Product Categories: 3-Aminopyrrolidines;Amines (Chiral);Chiral 3-Aminopyrrolidines;Chiral Building Blocks;Synthetic Organic Chemistry
• Mol File: 169749-99-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 273.066 °C at 760 mmHg
• Flash Point: 105.62 °C
• Appearance: /
• Density: 0,99 g/cm3
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 3 ° (C=10, EtOH)
• Storage Temp.: 2-8°C
• PKA: 10.16±0.20(Predicted)
• CAS DataBase Reference: (3S)-(+)-1-Benzyl-3-(methylamino)pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-(+)-1-Benzyl-3-(methylamino)pyrrolidine(169749-99-9)
• EPA Substance Registry System: (3S)-(+)-1-Benzyl-3-(methylamino)pyrrolidine(169749-99-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22-52
• RIDADR: 2735
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 169749-99-9(Hazardous Substances Data)

Usage

General Description

(3S)-(+)-1-Benzyl-3-(methylamino)pyrrolidine is a chemical compound with the molecular formula C14H20N2. It is a chiral compound with a three-dimensional arrangement of atoms, and the (3S)-(+)- configuration indicates the stereochemistry of the molecule. (3S)-(+)-1-Benzyl-3-(methylamino)pyrrolidine is commonly used in organic synthesis and medicinal chemistry as a building block for the synthesis of various pharmaceuticals and biologically active molecules. Its unique structure and properties make it valuable for the development of new drugs and other applications in the chemical and pharmaceutical industries.

InChI:InChI=1/C12H18N2/c1-13-12-7-8-14(10-12)9-11-5-3-2-4-6-11/h2-6,12-13H,7-10H2,1H3/t12-/m0/s1

Upstream product

• 131852-53-4 (S)-1-benzyl-3-(tert-butoxycarbonylamino)pyrrolidine 
• 116143-02-3 (3R)-1-(phenylmethyl)pyrrolidin-3-ol Acetate 
• 101385-90-4 (R)-N-benzyl-3-hydroxypyrrolidine 
• 101385-90-4 (S)-N-benzyl-3-hydroxypyrrolidine 
• 116183-80-3 (3R)-3-<(4-tolylsulfonyl)oxy>-1-(phenylmethyl)pyrrolidine 
• 74-89-5 methylamine 
• 116183-79-0 (3S)-3-<(4-tolylsulfonyl)oxy>-1-(phenylmethyl)pyrrolidine 

Downstream Products

• 1449203-54-6 C₂₃H₃₆N₄O₄ 
• 132920-84-4 (3S)-3-(methylamino)pyrrolidine dihydrochloride 
• 1396842-96-8 C₂₁H₁₉F₃N₄O₃S*C₂HF₃O₂ 
• 762285-82-5 C₂₅H₂₆N₂O 
• 762286-16-8 ((S)-1-{[(S)-1-(4,4-Dimethyl-cyclohexyl)-pyrrolidin-3-yl]-methyl-carbamoyl}-pyrrolidin-3-yl)-methyl-carbamic acid tert-butyl ester 
• 848464-94-8 ((R)-1-{[(S)-1-(4,4-Dimethyl-cyclohexyl)-pyrrolidin-3-yl]-methyl-carbamoyl}-pyrrolidin-3-yl)-methyl-carbamic acid tert-butyl ester 
• 762286-17-9 (S)-3-Methylamino-pyrrolidine-1-carboxylic acid [(S)-1-(4,4-dimethyl-cyclohexyl)-pyrrolidin-3-yl]-methyl-amide 
• 762285-86-9 {(S)-1-[((S)-1-Benzyl-pyrrolidin-3-yl)-methyl-carbamoyl]-pyrrolidin-3-yl}-methyl-carbamic acid tert-butyl ester 

Relevant articles and documents

JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF

Janus kinase 1 selective inhibitors and pharmaceutical use thereof are provided.

Fluoronaphthyridines and -quinolines as Antibacterial Agents. 5. Synthesis and Antimicrobial Activity of Chiral 1-tert-Butyl-6-fluoro-7-substituted-naphthyridones

A series of novel 7-substituted-1-tert-butyl-6-fluoronaphthyridone-3-carboxylic acids has been prepared.These derivatives are characterized by chiral aminopyrrolidine substituents at the 7 position.In this paper we report the full details of the asymmetric synthesis of this series of compounds.Structure-activity relationship studies indicate that the absolute stereochemistry at the asymmetric centers of the pyrrolidine ring is critical for maintaining good activity.Compounds 60 and 61 (3-amino-4-methylpyrrolidine enantiomers) were selected for preclinical evaluation.